{"id":"NCT04171414","sponsor":"Celltrion","briefTitle":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","officialTitle":"A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-09","primaryCompletion":"2019-11-04","completion":"2020-04-24","firstPosted":"2019-11-20","resultsPosted":"2021-11-17","lastUpdate":"2021-11-17"},"enrollment":62,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P17 SC AI (adalimumab)","otherNames":[]}],"arms":[{"label":"\"CT-P17 SC AI (adalimumab)\"","type":"EXPERIMENTAL"}],"summary":"Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","primaryOutcome":{"measure":"The Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4","timeFrame":"Week 4","effectByArm":[{"arm":"\"CT-P17 SC AI (Adalimumab)\"","deltaMin":8,"sd":2.131}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":62},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Diarrhoea","Headache","Hyperbilirubinaemia"]}}